Matrix Capital Management Company, LP 13D and 13G filings for Zentalis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-01-02 4:10 pm Sale | 2025-12-30 | 13D | Zentalis Pharmaceuticals, Inc. ZNTL | Matrix Capital Management Company, LP | 0 0.000% | -6,459,973 (Position Closed) | Filing |
| 2025-12-15 5:16 pm Sale | 2025-12-15 | 13D | Zentalis Pharmaceuticals, Inc. ZNTL | Matrix Capital Management Company, LP | 6,459,973 9.980% | -7,500,000 (-53.73%) | Filing |
| 2023-06-20 4:30 pm Purchase | 2023-06-20 | 13D | Zentalis Pharmaceuticals, Inc. ZNTL | Matrix Capital Management Company, LP | 13,959,973 19.810% | 4,760,000 (+51.74%) | Filing |
| 2022-06-03 10:52 am Purchase | 2022-05-18 | 13D | Zentalis Pharmaceuticals, Inc. ZNTL | Matrix Capital Management Company, LP | 9,199,973 16.450% | 4,850,694 (+111.53%) | Filing |
| 2022-02-14 12:03 pm Purchase | 2021-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | Matrix Capital Management Company, LP | 4,349,279 9.600% | 527,540 (+13.80%) | Filing |
| 2021-02-16 10:02 am Purchase | 2020-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | Matrix Capital Management Company, LP | 3,821,739 9.410% | 3,821,739 (New Position) | Filing |